Copy to clipboard 
DJO Global posted 1Q18 revenue of US $292.6MM, +1.5% vs. 1Q17.
ORTHOWORLD estimates segment sales and growth as follows.
| 1Q18 | 1Q17 | $ Change | % Change | |
| Joint Reconstruction | $71.0 | $60.2 | $10.8 | 17.9% |
| Knee | $19.2 | $16.0 | $3.2 | 20.2% |
| Hip | $16.7 | $14.5 | $2.2 | 15.4% |
| Extremities | $35.1 | $29.7 | $5.3 | 18.0% |
| Other* | $221.6 | $228.2 | -$6.5 | -2.9% |
| Total | $292.6 | $288.3 | $4.3 | 1.5% |
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
Hip and knee growth was somewhat slowed due to what leadership called the worst flu season in a decade, as well as a more substantial high deductible impact vs. the two previous years. Shoulders grew in double-digits.
As a bit of a history lesson, leaders noted that DJO has quadrupled its knee and hip business since 2014. In 2017, they didn’t follow the previous behavior of two to three launches per year. However, in 2018, they will essentially “catch up” as the year progresses.
DJO plans for seven surgical implant launches in 2018, six of which will address hip/knee. Three of them fall under what President/CEO Brady Shirley calls “significant business expansion launches.”
Leadership also expanded on a product mentioned in the 4Q17 call, the X4 Smart Brace. This device offers post-operative bracing, monitoring, interactive recovery and rehab guidance after knee procedures. It’s in early stages of being introduced in the market and generating tremendous interest. DJO will introduce a second product that is a tool for for ASC patient selection for the total knee, called Aura.
Sources: DJO Global, Inc.; ORTHOWORLD estimates
DJO Global posted 1Q18 revenue of US $292.6MM, +1.5% vs. 1Q17.
ORTHOWORLD estimates segment sales and growth as follows.
Q18
Q17
$ Change
% Change
Joint Reconstruction
$71.0
$60.2 ...
DJO Global posted 1Q18 revenue of US $292.6MM, +1.5% vs. 1Q17.
ORTHOWORLD estimates segment sales and growth as follows.
| 1Q18 | 1Q17 | $ Change | % Change | |
| Joint Reconstruction | $71.0 | $60.2 | $10.8 | 17.9% |
| Knee | $19.2 | $16.0 | $3.2 | 20.2% |
| Hip | $16.7 | $14.5 | $2.2 | 15.4% |
| Extremities | $35.1 | $29.7 | $5.3 | 18.0% |
| Other* | $221.6 | $228.2 | -$6.5 | -2.9% |
| Total | $292.6 | $288.3 | $4.3 | 1.5% |
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
Hip and knee growth was somewhat slowed due to what leadership called the worst flu season in a decade, as well as a more substantial high deductible impact vs. the two previous years. Shoulders grew in double-digits.
As a bit of a history lesson, leaders noted that DJO has quadrupled its knee and hip business since 2014. In 2017, they didn’t follow the previous behavior of two to three launches per year. However, in 2018, they will essentially “catch up” as the year progresses.
DJO plans for seven surgical implant launches in 2018, six of which will address hip/knee. Three of them fall under what President/CEO Brady Shirley calls “significant business expansion launches.”
Leadership also expanded on a product mentioned in the 4Q17 call, the X4 Smart Brace. This device offers post-operative bracing, monitoring, interactive recovery and rehab guidance after knee procedures. It’s in early stages of being introduced in the market and generating tremendous interest. DJO will introduce a second product that is a tool for for ASC patient selection for the total knee, called Aura.
Sources: DJO Global, Inc.; ORTHOWORLD estimates
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
